Although nanoparticle strategies targeting leukemia or lymphoma-specific markers such as CD19 and CD20 have been developed for other agents [100] and melittin-derived peptides have been incorporated into nanocomplexes for siRNA delivery in vitro [101], dedicated studies evaluating melittin-loaded formulations—such as liposomes or polymeric nanoparticles—for systemic delivery in leukemia or lymphoma models in vivo remain notably scarce in the recent literature. This evidence concerns the gene CD19 and lymphoma.